
J Christopher States

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9439757/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delineating the Effects of Passaging and Exposure in a Longitudinal Study of Arsenic-Induced Squamous Cell Carcinoma in a HaCaT Cell Line Model. Toxicological Sciences, 2022, 185, 184-196.	3.1	6
2	Temporal Modulation of Differential Alternative Splicing in HaCaT Human Keratinocyte Cell Line Chronically Exposed to Arsenic for up to 28 Wk. Environmental Health Perspectives, 2022, 130, 17011.	6.0	16
3	2020–2021 <i>Toxicological Sciences</i> Paper of the Year. Toxicological Sciences, 2022, 186, 177-178.	3.1	Ο
4	Chronic arsenic exposure suppresses ATM pathway activation in human keratinocytes. Toxicology and Applied Pharmacology, 2022, 446, 116042.	2.8	11
5	Zinc supplementation prevents arsenic-induced dysregulation of ZRANB2 splice function. Environmental Toxicology and Pharmacology, 2022, 94, 103921.	4.0	4
6	Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes. Archives of Toxicology, 2021, 95, 311-319.	4.2	6
7	miRNA dysregulation is an emerging modulator of genomic instability. Seminars in Cancer Biology, 2021, 76, 120-131.	9.6	49
8	Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Archives of Toxicology, 2021, 95, 2351-2365.	4.2	25
9	Role of Human N―Acetyltransferase 2 Genetic Polymorphism on Aromatic Amine Carcinogenâ€Induced DNA Damage and Mutagenicity in a Chinese Hamster Ovary Cell Mutation Assay. Environmental and Molecular Mutagenesis, 2020, 61, 235-245.	2.2	10
10	Arsenic-induced changes in miRNA expression in cancer and other diseases. Toxicology and Applied Pharmacology, 2020, 409, 115306.	2.8	56
11	Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms. Toxicology in Vitro, 2020, 67, 104925.	2.4	9
12	Chronic exposure to cadmium induces a malignant transformation of benign prostate epithelial cells. Oncogenesis, 2020, 9, 23.	4.9	26
13	Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing. Chemical Research in Toxicology, 2020, 33, 1403-1417.	3.3	19
14	Cadmium and High-Fat Diet Disrupt Renal, Cardiac and Hepatic Essential Metals. Scientific Reports, 2019, 9, 14675.	3.3	32
15	Overexpression of hsa-miR-186 induces chromosomal instability in arsenic-exposed human keratinocytes. Toxicology and Applied Pharmacology, 2019, 378, 114614.	2.8	16
16	High N-Acetyltransferase 1 Expression is Associated with Estrogen Receptor Expression in Breast Tumors, but is not Under Direct Regulation by Estradiol, 5 <i>α</i> -androstane-3 <i>β</i> , 17 <i>β</i> -Diol, or Dihydrotestosterone in Breast Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 84-93.	2.5	16
17	Differentially Expressed mRNA Targets of Differentially Expressed miRNAs Predict Changes in the TP53 Axis and Carcinogenesis-Related Pathways in Human Keratinocytes Chronically Exposed to Arsenic. Toxicological Sciences, 2018, 162, 645-654.	3.1	28
18	Genetic and small molecule inhibition of arylamine <i>N</i> â€acetyltransferase 1 reduces anchorageâ€independent growth in human breast cancer cell line MDAâ€MBâ€231. Molecular Carcinogenesis, 2018, 57, 549-558.	2.7	31

#	Article	IF	CITATIONS
19	Rapid onset of multiple concurrent squamous cell carcinomas associated with the use of an arsenic-containing traditional medicine for chronic plaque psoriasis. BMJ Case Reports, 2018, 2018, bcr-2017-222645.	0.5	9
20	Special Issue in Honor of Gordon H. Dixon. Systems Biology in Reproductive Medicine, 2018, 64, 399-402.	2.1	1
21	Arsenic-Induced Carcinogenesis: The Impact of miRNA Dysregulation. Toxicological Sciences, 2018, 165, 284-290.	3.1	32
22	miRNA expression profiles of premalignant and malignant arsenic-induced skin lesions. PLoS ONE, 2018, 13, e0202579.	2.5	38
23	Impact of prenatal arsenic exposure on chronic adult diseases. Systems Biology in Reproductive Medicine, 2018, 64, 469-483.	2.1	51
24	Cell cycle pathway dysregulation in human keratinocytes during chronic exposure to low arsenite. Toxicology and Applied Pharmacology, 2017, 331, 130-134.	2.8	12
25	Arsenic Carcinogenesis. Molecular and Integrative Toxicology, 2017, , 95-111.	0.5	Ο
26	Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. BMC Cancer, 2017, 17, 233.	2.6	15
27	Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1. Metabolomics, 2016, 12, 1.	3.0	23
28	Polychlorinated Biphenyl-Xenobiotic Nuclear Receptor Interactions Regulate Energy Metabolism, Behavior, and Inflammation in Non-alcoholic-Steatohepatitis. Toxicological Sciences, 2016, 149, 396-410.	3.1	56
29	Arsenic Disruption of DNA Damage Responses—Potential Role in Carcinogenesis and Chemotherapy. Biomolecules, 2015, 5, 2184-2193.	4.0	68
30	Disruption of Mitotic Progression by Arsenic. Biological Trace Element Research, 2015, 166, 34-40.	3.5	35
31	Folate-dependent hydrolysis of acetyl-coenzyme A by recombinant human and rodent arylamine N-acetyltransferases. Biochemistry and Biophysics Reports, 2015, 3, 45-50.	1.3	28
32	Human Receptor Activation by Aroclor 1260, a Polychlorinated Biphenyl Mixture. Toxicological Sciences, 2014, 140, 283-297.	3.1	81
33	Cisplatin Plus Sodium Arsenite and Hyperthermia Induces Pseudo-G1 Associated Apoptotic Cell Death in Ovarian Cancer Cells. Toxicological Sciences, 2014, 139, 74-82.	3.1	16
34	Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicology and Applied Pharmacology, 2014, 279, 380-390.	2.8	85
35	Systems approach to identify environmental exposures contributing to organ-specific carcinogenesis. Cancer Epidemiology, 2014, 38, 321-327.	1.9	5
36	Abstract 212: Withaferin A in combination with cisplatin targets CD44 and Oct4 positive cancer stem cells in ovarian cancer. , 2014, , .		0

#	Article	IF	CITATIONS
37	Delayed Temporal Increase of Hepatic Hsp70 in ApoE Knockout Mice After Prenatal Arsenic Exposure. Toxicological Sciences, 2013, 131, 225-233.	3.1	17
38	The Role of Arylamine Nâ€acetyltransferase 1 in Breast Cancer Progression. FASEB Journal, 2013, 27, lb579.	0.5	0
39	Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis, 2012, 33, 1431-1431.	2.8	0
40	Sodium Arsenite ± Hyperthermia Sensitizes p53-Expressing Human Ovarian Cancer Cells to Cisplatin by Modulating Platinum-DNA Damage Responses. Toxicological Sciences, 2012, 127, 139-149.	3.1	22
41	Phenotype of the Most Common "Slow Acetylator―Arylamine <i>N</i> -Acetyltransferase 1 Genetic Variant (<i>NAT1</i> * <i>14B</i>) Is Substrate-Dependent. Drug Metabolism and Disposition, 2012, 40, 198-204.	3.3	13
42	Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis, 2012, 33, 348-355.	2.8	16
43	Arsenic exposure through drinking water increases the risk of liver and cardiovascular diseases in the population of West Bengal, India. BMC Public Health, 2012, 12, 639.	2.9	105
44	Prenatal Arsenic Exposure Alters Gene Expression in the Adult Liver to a Proinflammatory State Contributing to Accelerated Atherosclerosis. PLoS ONE, 2012, 7, e38713.	2.5	58
45	Predicting Later-Life Outcomes of Early-Life Exposures. Environmental Health Perspectives, 2012, 120, 1353-1361.	6.0	155
46	NATb/ <i>NAT1*4</i> promotes greater arylamine <i>N</i> â€acetyltransferase 1 mediated DNA adducts and mutations than NATa/ <i>NAT1*4</i> following exposure to 4â€aminobiphenyl. Molecular Carcinogenesis, 2012, 51, 636-646.	2.7	18
47	Identification and Characterization of Novel Arylamine NAcetyltransferase Small Molecule Inhibitors. FASEB Journal, 2012, 26, 851.16.	0.5	0
48	Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. Toxicology and Applied Pharmacology, 2011, 257, 356-364.	2.8	70
49	Precancerous and non-cancer disease endpoints of chronic arsenic exposure: The level of chromosomal damage and XRCC3 T241M polymorphism. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 706, 7-12.	1.0	36
50	Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). Journal of Ovarian Research, 2011, 4, 9.	3.0	43
51	Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3′ untranslated regions. Birth Defects Research Part A: Clinical and Molecular Teratology, 2011, 91, 77-84.	1.6	18
52	Polymorphisms in the TNF-α and IL10 Gene Promoters and Risk of Arsenic-Induced Skin Lesions and Other Nondermatological Health Effects. Toxicological Sciences, 2011, 121, 132-139.	3.1	54
53	Arsenic Toxicology: Translating between Experimental Models and Human Pathology. Environmental Health Perspectives, 2011, 119, 1356-1363.	6.0	98
54	Abstract 1326: Systems approach to identifying potential environmental exposures playing a role in ovarian carcinogenesis. , 2011, , .		0

#	Article	IF	CITATIONS
55	No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate, 2010, 70, 113-119.	2.3	24
56	Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 684, 66-73.	1.0	19
57	Evaluation of the serum catalase and myeloperoxidase activities in chronic arsenic-exposed individuals and concomitant cytogenetic damage. Toxicology and Applied Pharmacology, 2010, 249, 47-54.	2.8	34
58	PAI-1 plays a protective role in CCl ₄ -induced hepatic fibrosis in mice: role of hepatocyte division. American Journal of Physiology - Renal Physiology, 2010, 298, G657-G666.	3.4	51
59	Suppression of p53 and p21 ^{CIP1/WAF1} Reduces Arsenite-Induced Aneuploidy. Chemical Research in Toxicology, 2010, 23, 357-364.	3.3	14
60	Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts. Xenobiotica, 2009, 39, 399-406.	1.1	13
61	Arsenic and Cardiovascular Disease. Toxicological Sciences, 2009, 107, 312-323.	3.1	280
62	Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicology and Applied Pharmacology, 2009, 241, 90-100.	2.8	94
63	Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role. Journal of Ovarian Research, 2009, 2, 2.	3.0	80
64	Functional effects of Nâ€acetyltransferase 1 (NAT1*10) polymorphisms. FASEB Journal, 2009, 23, LB394.	0.5	0
65	Subhepatotoxic exposure to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicology and Applied Pharmacology, 2008, 226, 128-139.	2.8	48
66	Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. Toxicology and Applied Pharmacology, 2008, 229, 252-261.	2.8	36
67	Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization. Toxicology and Applied Pharmacology, 2008, 230, 235-246.	2.8	31
68	Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent. Toxicology and Applied Pharmacology, 2008, 231, 61-67.	2.8	36
69	Quantitative Tissue and Gene-Specific Differences and Developmental Changes in <i>Nat1</i> , <i>Nat2</i> , and <i>Nat3</i> mRNA Expression in the Rat. Drug Metabolism and Disposition, 2008, 36, 2445-2451.	3.3	18
70	2-Amino-3,8-Dimethylimidazo-[4,5- <i>f</i>]Quinoxaline–Induced DNA Adduct Formation and Mutagenesis in DNA Repair–Deficient Chinese Hamster Ovary Cells Expressing Human Cytochrome P4501A1 and Rapid or Slow Acetylator <i>N</i> -Acetyltransferase 2. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1503-1509.	2.5	31
71	Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence Elements. Drug Metabolism and Disposition, 2007, 35, 1649-1656.	3.3	49
72	Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human Tissues. Drug Metabolism and Disposition, 2007, 35, 721-727.	3.3	83

#	Article	IF	CITATIONS
73	Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis, 2007, 28, 1665-1671.	2.8	91
74	Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenetics and Genomics, 2007, 17, 37-45.	1.5	26
75	2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-induced DNA adducts and genotoxicity in chinese hamster ovary (CHO) cells expressing human CYP1A2 and rapid or slow acetylator N-acetyltransferase 2. Molecular Carcinogenesis, 2007, 46, 553-563.	2.7	36
76	In utero arsenic exposure induces early onset of atherosclerosis in ApoEâ^'/â^' mice. Reproductive Toxicology, 2007, 23, 449-456.	2.9	71
77	Arseniteâ€induced mitotic death is distinct from both nocodazole and Taxol. FASEB Journal, 2007, 21, A806.	0.5	0
78	Sodium arsenite alters cell cycle progression and induces apoptosis in melanoma cell lines. FASEB Journal, 2007, 21, A806.	0.5	0
79	Early onset of atherosclerosis in ApoEâ€knockout mice is induced by in utero arsenic exposure. FASEB Journal, 2007, 21, A810.	0.5	1
80	Variant Base Excision Repair Genes (hOGG1, APE1, XRCC1) and Prostate Cancer Risk in Africanâ€American Men. FASEB Journal, 2007, 21, A421.	0.5	0
81	Functional analysis of the human Nâ€acetyltransferase 1 (NAT1) major promoter: Quantitation of tissue expression and identification of critical sequence elements. FASEB Journal, 2007, 21, A195.	O.5	Ο
82	Human rapid acetylator Nâ€acetyltransferase 2 (NAT2) genotype leads to greater mutagenesis and DNA damage than slow acetylator NAT2 genotype in DNAâ€deficient Chinese Hamster Ovary (CHO) cells treated with arylamine carcinogens. FASEB Journal, 2007, 21, A414.	0.5	0
83	Significantly higher 2â€aminoâ€3,8â€dimethylimidazoâ€[4,5â€f]quinoxaline–induced DNA adducts and mutagenesis in Chinese hamster ovary cells expressing human CYP1A1 and rapid or slow acetylator Nâ€acetyltransferase 2. FASEB Journal, 2007, 21, A414.	0.5	0
84	Robust Incision of Benoz[a]pyrene-7,8-dihyrodiol-9,10-epoxideâ^'DNA Adducts by a Recombinant Thermoresistant Interspecies Combination UvrABC Endonuclease Systemâ€. Biochemistry, 2006, 45, 7834-7843.	2.5	11
85	Telomerase-immortalized human fibroblasts retain UV-induced mutagenesis and p53-mediated DNA damage responses. DNA Repair, 2006, 5, 61-70.	2.8	7
86	Incision of trivalent chromium [Cr(III)]-induced DNA damage by Bacillus caldotenax UvrABC endonuclease. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2006, 610, 85-92.	1.7	14
87	Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenetics and Genomics, 2006, 16, 515-525.	1.5	46
88	Exit from Arsenite-Induced Mitotic Arrest Is p53 Dependent. Environmental Health Perspectives, 2006, 114, 1401-1406.	6.0	19
89	p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 142-151.	2.5	47
90	Arsenite Delays Progression through Each Cell Cycle Phase and Induces Apoptosis following G ₂ /M Arrest in U937 Myeloid Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 877-887.	2.5	55

#	Article	IF	CITATIONS
91	XP-A cells complemented with Arg228Gln and Val234Leu polymorphic XPA alleles repair BPDE-induced DNA damage better than cells complemented with the wild type allele. DNA Repair, 2005, 4, 341-349.	2.8	17
92	Retention of Cr(III) by high-performance chelation ion chromatography interfaced to inductively-coupled plasma mass spectrometric detection with collision cell. Journal of Chromatography A, 2004, 1024, 129-137.	3.7	26
93	Supercoiled DNA Promotes Formation of Intercalated cis-N2-Deoxyguanine Adducts and Base-Stacked trans-N2-Deoxyguanine Adducts by (+)-7R,8S-Dihydrodiol-9S,10R-epoxy-7,8,9,10-tetra-hydrobenzo[a]pyrene. Chemical Research in Toxicology, 2004, 17, 330-339.	3.3	12
94	Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics and Genomics, 2004, 14, 397-406.	5.7	50
95	The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics and Genomics, 2004, 14, 717-723.	5.7	57
96	Reduced sulfhydryls maintain specific incision of BPDE–DNA adducts by recombinant thermoresistant Bacillus caldotenax UvrABC endonuclease. Protein Expression and Purification, 2003, 31, 88-98.	1.3	8
97	Polymorphisms in the human xeroderma pigmentosum group A gene and their impact on cell survival and nucleotide excision repair. DNA Repair, 2002, 1, 531-546.	2.8	39
98	Tryptophan Hydroxylase: Cloning and Expression of the Rat Brain Enzyme in Mammalian Cells. Journal of Neurochemistry, 2002, 67, 900-906.	3.9	21
99	Arsenite Disrupts Mitosis and Induces Apoptosis in SV40-Transformed Human Skin Fibroblasts. Toxicology and Applied Pharmacology, 2002, 180, 83-91.	2.8	50
100	The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International Journal of Oncology, 2001, 19, 1089-97.	3.3	6
101	Metals and Disorders of Cell Accumulation: Modulation of Apoptosis and Cell Proliferation. Toxicological Sciences, 2000, 56, 255-261.	3.1	104
102	Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 724-33.	2.5	40
103	A summary of mutations in the UV-sensitive disorders: Xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Human Mutation, 1999, 14, 9-22.	2.5	198
104	Distribution of mutations in the human xeroderma pigmentosum group A gene and their relationships to the functional regions of the DNA damage recognition protein. Human Mutation, 1998, 12, 103-113.	2.5	60
105	The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein. Biochemical Journal, 1997, 328, 1-12.	3.7	92
106	Phosphorylation and Activation of Brain Tryptophan Hydroxylase: Identification of Serineâ€58 as a Substrate Site for Protein Kinase A. Journal of Neurochemistry, 1997, 68, 2220-2223.	3.9	42
107	Splice site mutations in a xeroderma pigmentosum group A patient with delayed onset of neurological disease. Mutation Research DNA Repair, 1996, 363, 171-177.	3.7	14
108	Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Letters, 1996, 108, 233-237.	7.2	27

#	Article	IF	CITATIONS
109	Preferential DNA damage in thep53 gene by benzo[a]pyrene metabolites in cytochrome P4501A1-expressing xeroderma pigmentosum group A cells. , 1996, 16, 32-43.		13
110	Stable transformation of xeroderma pigmentosum group A cells with an XPA minigene restores normal DNA repair and mutagenesis of UV-treated plasmids. Carcinogenesis, 1996, 17, 1909-1917.	2.8	12
111	Differential mutagenicity and cytotoxicity of (±)-benzo[a]pyrene-trans-7,8-dihydrodiol and (±)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9, 10-epoxide in genetically engineered human fibroblasts. Molecular Carcinogenesis, 1995, 12, 91-102.	2.7	13
112	Characterization of the human XPA promoter. Gene, 1995, 166, 341-342.	2.2	8
113	Cytotoxicity and genotoxicity of (±)-benzo[a]pyrene-trans-7,8-dihydrodiol in CYP1A1-expressing human fibroblasts quantitatively correlate with CYP1A1 expression level. Carcinogenesis, 1994, 15, 1827-1832.	2.8	10
114	Expression of human cytochrome P450 1A1 in DNA repair deficient and proficient human fibroblasts stably transformed with an inducible expression vector. Carcinogenesis, 1993, 14, 1643-1649.	2.8	23
115	Co-Induction of Tetrahydrobiopterin (BH4) Levels and Tyrosine Hydroxylase Activity in Cultured PC12 Cells. Advances in Experimental Medicine and Biology, 1993, 338, 227-230.	1.6	4
116	An STS in the human skeletal α-actin gene. Nucleic Acids Research, 1991, 19, 5086-5086.	14.5	0
117	An STS in the human cytoskeletal γ-actin gene. Nucleic Acids Research, 1991, 19, 5085-5085.	14.5	0
118	An STS in the human adenosine deaminase gene (located 20q12-q13.11). Nucleic Acids Research, 1991, 19, 5084-5084.	14.5	1
119	A gel electrophoresis system for resolving over 500 nucleotides with a single sample loading. BioTechniques, 1991, 11, 46-8.	1.8	1
120	Evidence for increased translational efficiency in the induction of P450IIE1 by solvents: Analysis of P450IIE1 mRNA polyribosomal distribution. Biochemical and Biophysical Research Communications, 1990, 172, 767-774.	2.1	53
121	Cell type-specific transcriptional regulation of the human adenosine deaminase gene. Nucleic Acids Research, 1989, 17, 1061-1076.	14.5	64
122	A new family of repetitive, retroposonâ€like sequences in the genome of the rainbow trout. FEBS Journal, 1988, 176, 255-264.	0.2	28
123	Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts Journal of Biological Chemistry, 1988, 263, 16291-16296.	3.4	28
124	Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements Journal of Clinical Investigation, 1988, 81, 1323-1327.	8.2	88
125	Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5947-5951.	7.1	54
126	Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency. Journal of Immunology, 1987, 138, 3203-6.	0.8	30

#	ARTICLE	IF	CITATIONS
127	Isolation and fractionation of total nucleic acids from tissues and cells. Journal of Proteomics, 1986, 12, 29-36.	2.4	33
128	Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry, 1986, 25, 8234-8244.	2.5	160
129	Evidence of sequences resembling avian retrovirus long terminal repeats flanking the trout protamine gene. Journal of Molecular Evolution, 1986, 23, 1-10.	1.8	59
130	General method for isolation of DNA sequences that interact with specific nuclear proteins in chromosomes: binding of the high mobility group protein HMG-T to a subset of the protamine gene family. Biochemistry, 1985, 24, 8021-8028.	2.5	19
131	Organization and Evolution of the Protamine Genes of Salmonid Fishes. , 1985, , 287-314.		18
132	Organization of the histone genes in the rainbow trout (Salmo gairdnerii). Journal of Molecular Evolution, 1984, 20, 227-235.	1.8	36
133	Organization and nucleotide sequence of rainbow trout histone H2A and H3 genes. Journal of Molecular Evolution, 1984, 20, 236-250.	1.8	24
134	Increased thermal stability of solubilized chromatin after poly(ADP-ribose) synthesis. Bioscience Reports, 1983, 3, 847-856.	2.4	1
135	Sequence homologtes in the protamine gene family of rainbow trout. Nucleic Acids Research, 1983, 11, 4907-4922.	14.5	46
136	Nucleotide sequence of a protamine component ClIgene ofSalmo gairdnerii. Nucleic Acids Research, 1982, 10, 4551-4563.	14.5	41
137	Poly (ADP-ribose) polymerase activity of aortic nuclei from swine on hyperlipemic diet. Journal of Molecular and Cellular Cardiology, 1982, 14, 63-70.	1.9	1